Indian Pharma is Progressing

Among the US President Donald Trump’s tariff blackmails, the most consequential is a proposed 25 percent tariff hike on pharmaceutical imports. India and China remain pivotal players in the generic drug supply chain to the US Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance (IPA), recently emphasized that Indian pharmaceutical firms contribute nearly 47 percent of the generic medicines imported by the U.S., underscoring their role in delivering affordable, quality-assured treatments.

However, the tariff decision introduces a new layer of complexity. President Trump has indicated that

companies may seek exemptions by establishing manufacturing facilities within the US, potentially incentivizing Indian firms to localize operations. This development arrives at a time when India is gaining momentum on the global pharmaceutical stage, with innovation and expansion driving its strategic outlook.

A timely reflection of this progress is the upcoming 74th Indian Pharmaceutical Congress (IPC), set to take place in Bengaluru in December 2025. As India’s most prominent annual pharma event, IPC will convene stakeholders from industry, academia, and regulatory bodies to spotlight advancements in drug development, manufacturing, and healthcare delivery. The conference is expected to host a diverse mix of professionals and students, fostering dialogue on how Indian pharma can navigate emerging global challenges and opportunities.

As this special issue highlights some of India’s most reputed pharmaceutical and life sciences leaders who are piloting this transformation. We welcome your thoughts on how Indian pharmaceutical companies can adapt and thrive in this shifting global environment.